Labcorp Holdings Inc. shares reached a record $339.78 on Thursday, extending gains following a second-quarter earnings beat that exceeded analyst expectations.
The company’s stock was last trading at $339.63, just 1% below its 52-week high, after reporting adjusted earnings of $4.99 per share. This compared with forecasts of $4.79 per share and an increase from $4.34 in the prior-year period. Revenue rose 5.8% to $3.73 billion, slightly above market projections.
Labcorp also raised its full-year outlook, providing an upward revision to its guidance following the stronger-than-expected performance. The company’s year-to-date return stands at 34.52%, while its 12-month gain totals 23.22%.
Executive leadership changes were also noted, with Megan D. Bailey, Executive Vice President and President of Central Laboratories and International, set to depart effective September 4, 2026. Eleven analysts have revised their earnings estimates higher for the coming period, according to InvestingPro data, though the stock is flagged as potentially overvalued relative to its Fair Value estimate.
InvestingPro data indicated the stock may be trading above its estimated fair value, while additional analyst commentary and research tools were cited as available through the platform.
